ALUNBRIG
Total Payments
$55.2M
Transactions
11,486
Doctors
4,343
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 3,442 | 2,348 |
| 2023 | $12.6M | 2,641 | 1,751 |
| 2022 | $13.0M | 1,272 | 828 |
| 2021 | $19.6M | 1,099 | 647 |
| 2020 | $3.5M | 725 | 243 |
| 2019 | $1.5M | 592 | 54 |
| 2018 | $2.4M | 818 | 141 |
| 2017 | $1.2M | 897 | 244 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $49.9M | 731 | 90.5% |
| Consulting Fee | $2.3M | 535 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 643 | 3.4% |
| Travel and Lodging | $498,121 | 1,267 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $359,650 | 136 | 0.7% |
| Food and Beverage | $244,753 | 7,938 | 0.4% |
| Education | $2,926 | 236 | 0.0% |
Payments by Type
Research
$49.9M
731 transactions
General
$5.2M
10,755 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| BRIGHTSTAR: A PILOT TRIAL OF LOCAL CONSOLIDATIVE THERAPY (LCT) WITH BRIGATINIB IN TYROSINE KINASE INHIBITOR-NA?VE ALK-REARRANGED ADVANCED NSCLC | Takeda Pharmaceuticals U.S.A., Inc. | $20.6M | 0 |
| INNOVATIVE TRIAL FOR UNDERSTANDING THE IMPACT OF TARGETED THERAPIES IN NF2 (INTUITT-NF2) | Takeda Pharmaceuticals U.S.A., Inc. | $20.5M | 0 |
| PHASE IB STUDY OF BRIGATINIB PLUS BEVACIZUMAB IN PATIENTS WITH ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PREVIOUSLY PROGRESSED ON PRIOR ALK-DIRECTED THERAPY | Takeda Pharmaceuticals U.S.A., Inc. | $1.3M | 0 |
| A PHASE II TRIAL OF BRIGATINIB ALONE WITHOUT RADIATION FOR SYMPTOMATIC BRAIN METASTASES ALK+ LUNG CANCER | Takeda Pharmaceuticals U.S.A., Inc. | $1.1M | 0 |
| Phase 2 trial Brigatinib in patients with advanced ALK rearranged NSCLC who have progressed after a second generation ALK inhibitor | Takeda Pharmaceuticals U.S.A., Inc. | $706,790 | 0 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY OF BRIGATINIB (ALUNBRIG?) VERSUS ALECTINIB (ALECENSA?) IN ADVANCED ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL-CELL LUNG CANCER PATIENTS WHO HAVE PROGRESSED ON CRIZOTINIB (XALKORI?) | Takeda Pharmaceuticals U.S.A., Inc. | $675,091 | 5 |
| TREATMENT PATTERNS, MECHANISMS OF RESISTANCE AND OUTCOMES AMONG PATIENTS WITH ALK AND ROS1 TRANSLOCATED NON-SMALL CELL LUNG CANCER: AN ATOMIC CONSORTIUM ANALYSIS | Takeda Pharmaceuticals U.S.A., Inc. | $640,353 | 0 |
| A phase I study of brigatinib with binimetinib in advanced ALK- or ROS1-rearranged non-small cell lung cancer (NSCLC) | Takeda Pharmaceuticals U.S.A., Inc. | $625,350 | 0 |
| PHASE 2 TRIAL BRIGATINIB IN PATIENTS WITH ADVANCED ALK REARRANGED NSCLC WHO HAVE PROGRESSED AFTER A SECOND GENERATION ALK INHIBITOR | Takeda Pharmaceuticals U.S.A., Inc. | $542,271 | 0 |
| ALTA-1L STUDY: A PHASE 3 STUDY OF BRIGATINIB VERSUS CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PARTICIPANTS | Takeda Pharmaceuticals U.S.A., Inc. | $523,605 | 1 |
| A PHASE 1/2 STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF THE ORAL ALK/EGFR INHIBITOR AP26113 | Takeda Pharmaceuticals U.S.A., Inc. | $508,508 | 0 |
| Pulmonary Physiology and Systemic Inflammatory Signature Investigations into Early Onset Pulmonary Events Associated with Brigatinib use in Non-Small Cell Lung Cancer | Takeda Pharmaceuticals U.S.A., Inc. | $453,740 | 0 |
| Treatment Patterns, Mechanisms of Resistance and Outcomes among patients with ALK and ROS1 Translocated Non-Small Cell Lung Cancer: An ATOMIC Consortium Analysis | Takeda Pharmaceuticals U.S.A., Inc. | $389,174 | 0 |
| BRIGATINIB IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+), ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PROGRESSED ON ALECTINIB OR CERITINIB | Takeda Pharmaceuticals U.S.A., Inc. | $363,546 | 1 |
| A STUDY TO EVALUATE THE EFFICACY OF BRIGATINIB (AP26113) IN PARTICIPANTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE, NON-SMALL CELL LUNG CANCER (NSCLC) PREVIOUSLY TREATED WITH CRIZOTINIB | Takeda Pharmaceuticals U.S.A., Inc. | $298,674 | 0 |
| PULMONARY PHYSIOLOGY AND SYSTEMIC INFLAMMATORY SIGNATURE INVESTIGATIONS INTO EARLY ONSET PULMONARY EVENTS ASSOCIATED WITH BRIGATINIB USE IN NON-SMALL CELL LUNG CANCER | Takeda Pharmaceuticals U.S.A., Inc. | $245,672 | 0 |
| PHASE IB STUDY OF BRIGATINIB PLUS BEVACIZUMAB IN PATIENTS WITH ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PREVIOUSLY PROGRESSED ON PRIOR ALK-DIRECTED THERAPY | Takeda Pharmaceuticals U.S.A., Inc. | $133,300 | 0 |
| Study of Plasma next generation sequencing for remote Assessment, Characterization, Evaluation of patients With ALK drug resistance (SPACEWALK) | Takeda Pharmaceuticals U.S.A., Inc. | $120,000 | 0 |
| Phase II study of brigatinib for advanced solid cancers harboring genomic alterations in ALK and ROS1 oncogenes | Takeda Pharmaceuticals U.S.A., Inc. | $92,679 | 0 |
| A Phase II Study of Brigatinib in Relapsed or Refractory ALK-positive Anaplastic Large Cell Lymphoma | Takeda Pharmaceuticals U.S.A., Inc. | $78,876 | 0 |
Top Doctors Receiving Payments for ALUNBRIG
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $50.3M | 863 |
| , MD | Internal Medicine | Tampa, FL | $249,142 | 187 |
| , MD | Hematology & Oncology | Deerfield Beach, FL | $247,272 | 117 |
| , M.D | Hematology & Oncology | Orlando, FL | $220,244 | 148 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | Pembroke Pines, FL | $203,592 | 155 |
| , MD | Medical Oncology | Grand Rapids, MI | $164,786 | 99 |
| , MD | Hematology & Oncology | New Orleans, LA | $146,700 | 83 |
| , MD PHD | Hematology & Oncology | Orange, CA | $131,716 | 77 |
| , MD | Medical Oncology | Aurora, CO | $129,485 | 52 |
| , MD | Hematology & Oncology | Philadelphia, PA | $127,841 | 87 |
| , M.D | Hematology & Oncology | Mountain View, CA | $116,551 | 100 |
| , MD | Medical Oncology | El Paso, TX | $96,187 | 85 |
| , MD | Medical Oncology | Seattle, WA | $78,978 | 58 |
| , M.D | Hematology & Oncology | La Jolla, CA | $74,467 | 44 |
| , MD | Hematology & Oncology | Orange, CA | $66,543 | 36 |
| , MD | Hematology & Oncology | Orlando, FL | $64,290 | 44 |
| , MD | Internal Medicine | Boston, MA | $62,400 | 30 |
| , MD | Hematology & Oncology | Chandler, AZ | $58,181 | 45 |
| , MD | Medical Oncology | Phoenix, AZ | $55,627 | 47 |
| , MD, PHD | Hematology & Oncology | Nashville, TN | $54,968 | 43 |
| , MD | Medical Oncology | Los Angeles, CA | $52,331 | 26 |
| , M.D | Medical Oncology | San Antonio, TX | $51,889 | 28 |
| , MD | Medical Oncology | Columbus, OH | $50,503 | 34 |
| , MD | Internal Medicine | Philadelphia, PA | $49,394 | 38 |
| , M.D | Hematology & Oncology | Washington, DC | $46,045 | 22 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $55.2M
- Total Doctors 4,343
- Transactions 11,486
About ALUNBRIG
ALUNBRIG is a drug associated with $55.2M in payments to 4,343 healthcare providers, recorded across 11,486 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2024. In 2024, $1.4M was paid across 3,442 transactions to 2,348 doctors.
The most common payment nature for ALUNBRIG is "Unspecified" ($49.9M, 90.5% of total).
ALUNBRIG is associated with 20 research studies, including "BRIGHTSTAR: A PILOT TRIAL OF LOCAL CONSOLIDATIVE THERAPY (LCT) WITH BRIGATINIB IN TYROSINE KINASE INHIBITOR-NA?VE ALK-REARRANGED ADVANCED NSCLC" ($20.6M).